Indivior Pharmaceuticals, Inc. (DELISTED) (INDV:DL)
36.28
+0.91
(+2.57%)
USD |
NASDAQ |
Nov 02, 16:00
Indivior Pharmaceuticals Gross Profit Margin (Quarterly) : 85.67% for Sept. 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 85.67% |
| June 30, 2026 | 85.42% |
| March 31, 2026 | 87.38% |
| December 31, 2025 | 82.12% |
| September 30, 2025 | 80.25% |
| June 30, 2025 | 82.78% |
| March 31, 2025 | 83.46% |
| December 31, 2024 | 83.89% |
| September 30, 2024 | 78.50% |
| June 30, 2024 | 73.58% |
| March 31, 2024 | 86.62% |
| December 31, 2023 | 81.57% |
| September 30, 2023 | 80.81% |
| June 30, 2023 | 80.80% |
| March 31, 2023 | 83.00% |
| December 31, 2022 | 80.58% |
| September 30, 2022 | 81.03% |
| June 30, 2022 | 81.00% |
| March 31, 2022 | 80.68% |
| December 31, 2021 | 81.53% |
| September 30, 2021 | 83.96% |
| June 30, 2021 | 82.59% |
| March 31, 2021 | 80.56% |
| December 31, 2020 | 82.70% |
| Date | Value |
|---|---|
| September 30, 2020 | 80.50% |
| June 30, 2020 | 84.67% |
| March 31, 2020 | 85.62% |
| December 31, 2019 | 63.91% |
| September 30, 2019 | 80.40% |
| June 30, 2019 | 86.05% |
| March 31, 2019 | 82.77% |
| December 31, 2018 | 83.47% |
| September 30, 2018 | 84.49% |
| June 30, 2018 | 85.82% |
| March 31, 2018 | 89.41% |
| December 31, 2017 | 86.42% |
| September 30, 2017 | 88.36% |
| June 30, 2017 | 90.62% |
| March 31, 2017 | 92.08% |
| December 31, 2016 | 88.03% |
| September 30, 2016 | 90.30% |
| June 30, 2016 | 85.77% |
| March 31, 2016 | 89.53% |
| December 31, 2015 | 84.27% |
| September 30, 2015 | 87.95% |
| June 30, 2015 | 88.72% |
| March 31, 2015 | 88.05% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Supernus Pharmaceuticals, Inc. | 77.67% |
| Bristol Myers Squibb Co. | 64.79% |
| Eli Lilly & Co. | 83.88% |
| Ligand Pharmaceuticals, Inc. | 83.68% |
| Amneal Pharmaceuticals, Inc. | 38.73% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Assets | 35.26% |
| Return on Invested Capital | 149.1% |
| Profit Margin (Quarterly) | 38.48% |
| Operating Margin (Quarterly) | 52.25% |
| Return on Net Operating Assets | 72.58% |